Demand For Innovative Approaches in Drug Discovery Programs to Propel the Adoption of Label Free Detection Technologies

Label Free Detection Market

Globally, the drug discovery programs have been increasing since the last couple of decades, becoming a direct influencing factor to the growth of the global label free detection market.  This is due to increasing need for new drug development in response to the growing prevalence of various chronic diseases. Label free detection technologies have been an important tool in the manufacturing and developing drugs. The drug discovery programs involve a large variety of profiling in order to define activity, selectivity, potency, adverse effects, pharmacology, and in vivo efficacy of drugs. According to the National Center for Biotechnology Information (NCBI), the label free detection technologies plays major role in the target selection till the development of drug. The most crucial step in the drug development is to understand the molecular interactions. This can be easily detected using label free detection technologies which can be used for both communicable and non-communicable diseases.

According to the World Cancer Research Fund International (WCRFI), in 2012, there were an estimated 14.1 million new cancer cases worldwide, and this number is expected to increase to 19.3 million by 2025 and 24.0 million by 2035. The most of the cancer patients have undiagnosed depression due to lack of knowledge about the cause and treatment of cancers. Also, previously, the cancers which found to be visible were detected using MRI and CT scan. However, the complexities of the developing cancer make researchers difficult to understand the treatment for the same. The most chronic diseases are due to abnormal protein-protein interactions and hence need to be detected at molecular level. The development of the drug is possible only when the disease is diagnosed at cellular and molecular level. Currently, drug discovery programs have been used for pediatric cancer treatment.

According to the Drug Discovery Magazine, in 2017, the drug discovery programs have been increasing for the detection of tuberculosis and anticancer drug therapy. From 1990 to 2013, the number of new and relapsed cases of tuberculosis increased from 3.74 million to 5.73 million across the globe. According to the Drug Discovery Today, in 2017, the label free whole cell assay is used for the detection of structural and molecular cause of tuberculosis and thereby helps in development of drug design. In addition, about 207.4 million people were suffered from malaria across the world in 2012. Also, according to the Centers for Disease Control and Prevention (CDC), about one in three American adults will have diabetes by 2050.

In addition, it was found that the number of chronic diseases is rapidly increasing in developing countries compared to developed ones. According to the World Health Organization (WHO), the burden of major chronic diseases is expected to increase to 73% of all deaths by 2020. This is mainly due to unhealthy life style, lack of awareness about emerging technologies, and high cost of detection leading to less use of healthcare services. According to the NCBI, recently, the researchers are giving major focus on the development of generic and targeted drugs using label free technologies.

Thus, rising prevalence of chronic diseases across the world increases the need for sophisticated and reliable instruments and technologies for rapid detection of diseases and development of targeted drugs; thereby driving the label free detection market across the globe. Owing to the unique properties and increasing adoption in various drug discovery programs and other research activities, label free detection technologies has been witnessing a rapid growth in the global market. Label free detection market is expected to grow at CAGR of 8.8% to reach USD 2,292.0 million by 2022, according to the Meticulous Research™.

Browse in depth Report: Label Free Detection Market – Global Opportunity Analysis and Industry Forecast (2017-2022)

Leave a Reply

Your email address will not be published. Required fields are marked *